DNA OYJ |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.10% | -0.10% |
| Apr. 16 | DNA Oyj Announces Change in the Executive Team | CI |
| Feb. 07 | Eltel and DNA Renew One-Year Telecom Frame Agreement in Finland Worth About EUR 12.5 Million | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,257 | 2,757 | 2,755 | 2,755 | 2,755 | 2,755 |
| Enterprise Value (EV) 1 | 2,636 | 3,316 | 3,352 | 3,246 | 3,389 | 3,425 |
| P/E ratio | 22.2 x | 27.9 x | 24 x | 23.4 x | 22.9 x | 18.8 x |
| Yield | 4.1% | - | - | 7.29% | 3.65% | 2.21% |
| Capitalization / Revenue | 2.48 x | 2.93 x | 2.95 x | 2.88 x | 2.76 x | 2.58 x |
| EV / Revenue | 2.89 x | 3.52 x | 3.59 x | 3.4 x | 3.4 x | 3.21 x |
| EV / EBITDA | 9.26 x | 11.5 x | 10.9 x | 10.4 x | 10.7 x | 10.1 x |
| EV / FCF | 90.1 x | 28.7 x | 36.8 x | 23.7 x | 40.5 x | 21.8 x |
| FCF Yield | 1.11% | 3.48% | 2.72% | 4.22% | 2.47% | 4.59% |
| Price to Book | 3.73 x | 5 x | 4.19 x | 3.58 x | 4.15 x | 4.29 x |
| Nbr of stocks (in thousands) | 132,121 | 132,182 | 132,182 | 132,182 | 132,182 | 132,182 |
| Reference price 2 | 17.08 | 20.86 | 20.84 | 20.84 | 20.84 | 20.84 |
| Announcement Date | 3/1/19 | 2/28/20 | 3/4/21 | 3/8/22 | 3/8/23 | 3/7/24 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 911.8 | 942.1 | 934.5 | 956 | 997.1 | 1,067 |
| EBITDA 1 | 284.6 | 288.1 | 306.5 | 310.8 | 316.4 | 340.2 |
| EBIT 1 | 138.5 | 134.2 | 151.4 | 154.2 | 160.2 | 199.6 |
| Operating Margin | 15.2% | 14.24% | 16.2% | 16.13% | 16.07% | 18.7% |
| Earnings before Tax (EBT) 1 | 127.7 | 124.6 | 143.4 | 147.3 | 151 | 182.7 |
| Net income 1 | 102.2 | 98.82 | 114.8 | 117.7 | 120.3 | 146.2 |
| Net margin | 11.21% | 10.49% | 12.28% | 12.32% | 12.07% | 13.7% |
| EPS 2 | 0.7700 | 0.7481 | 0.8685 | 0.8900 | 0.9100 | 1.106 |
| Free Cash Flow 1 | 29.24 | 115.4 | 91.04 | 137.1 | 83.57 | 157.2 |
| FCF margin | 3.21% | 12.24% | 9.74% | 14.34% | 8.38% | 14.74% |
| FCF Conversion (EBITDA) | 10.28% | 40.05% | 29.7% | 44.12% | 26.42% | 46.22% |
| FCF Conversion (Net income) | 28.6% | 116.74% | 79.31% | 116.45% | 69.46% | 107.58% |
| Dividend per Share 2 | 0.7000 | - | - | 1.520 | 0.7600 | 0.4600 |
| Announcement Date | 3/1/19 | 2/28/20 | 3/4/21 | 3/8/22 | 3/8/23 | 3/7/24 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 379 | 559 | 597 | 492 | 634 | 670 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.333 x | 1.941 x | 1.949 x | 1.582 x | 2.004 x | 1.97 x |
| Free Cash Flow 1 | 29.2 | 115 | 91 | 137 | 83.6 | 157 |
| ROE (net income / shareholders' equity) | 16.9% | 17.1% | 19% | 16.5% | 16.8% | 22.4% |
| ROA (Net income/ Total Assets) | 6.81% | 6.08% | 6.2% | 5.91% | 6% | 7.27% |
| Assets 1 | 1,501 | 1,624 | 1,852 | 1,993 | 2,004 | 2,009 |
| Book Value Per Share 2 | 4.580 | 4.170 | 4.970 | 5.820 | 5.020 | 4.860 |
| Cash Flow per Share 2 | 0.1700 | 0.1300 | 0.0600 | 0.0800 | 0.0600 | 0.0300 |
| Capex 1 | 145 | 133 | 172 | 161 | 148 | 142 |
| Capex / Sales | 15.91% | 14.1% | 18.42% | 16.8% | 14.84% | 13.32% |
| Announcement Date | 3/1/19 | 2/28/20 | 3/4/21 | 3/8/22 | 3/8/23 | 3/7/24 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- DNA Stock
- Financials DNA Oyj
